UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. )*
MBX Biosciences, Inc.
(Name of Issuer)
Common stock, $0.0001 par value per share
(Title of Class of
Securities)
55287L101
(CUSIP Number)
Matthew De Dominicis
Chief Financial Officer
Norwest Venture Partners
1300 El Camino Real, Suite 200
Menlo Park, CA 94024
(650) 321-8000
(Name, Address
and Telephone Number of Person
Authorized to Receive Notices and Communications)
September 16, 2024
(Date of Event
Which Requires Filing of this Statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D,
and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨
Note:
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7
for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled
out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover
page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act")
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
| CUSIP
No. 55287L101 |
| 1. |
Names of Reporting Persons
Norwest Venture Partners XVI, LP |
| 2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨ (b) x
(1) |
| 3. |
SEC
Use Only |
| 4. |
Source of Funds (See Instructions)
WC |
| 5. |
Check
if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨ |
| 6. |
Citizenship or Place of Organization
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
7. |
Sole Voting Power
0 |
| 8. |
Shared Voting Power
2,136,335 shares (2) |
| 9. |
Sole Dispositive Power
0 |
| 10. |
Shared Dispositive Power
2,136,335 shares (2) |
| 11. |
Aggregate Amount Beneficially Owned by Each Reporting Person
2,136,335 shares (2) |
| 12. |
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ |
| 13. |
Percent of Class Represented by Amount in Row (11)
6.4% (3) |
| 14. |
Type of Reporting Person (See Instructions)
PN |
| |
|
|
|
| (1) | This Schedule 13D is filed by Norwest Venture
Partners XVI, LP (“NVP XVI”), Genesis VC Partners XVI, LLC (“Genesis XVI”),
NVP Associates, LLC (“NVP Associates”), Jeffrey Crowe (“Crowe”),
Jon E. Kossow (“Kossow”) and Tiba Aynechi (“Aynechi” and, with NVP
XVI, Genesis XVI, NVP Associates, Crowe and Kossow, collectively, the “Reporting Persons”).
The Reporting Persons expressly disclaim status as a “group” for purposes of
this Schedule 13D. |
| (2) | Shares are directly held by NVP XVI. Genesis
XVI is the general partner of NVP XVI, NVP Associates is the managing member of Genesis XVI,
Crowe and Kossow are Co-Chief Executive Officers of NVP Associates, and Aynechi is an officer
of NVP Associates and a director of the Issuer. Each of Genesis XVI, NVP Associates, Crowe,
Kossow and Aynechi, may be deemed to share voting and investment authority over these shares. |
| (3) | Calculation of the percentage of common stock
beneficially owned is based upon 31,853,698 shares of Common Stock outstanding as of September 16,
2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s
final prospectus filed with the Securities and Exchange Commission (the “SEC”)
on September 13, 2024 and giving effect to an additional 1,530,000 shares issued and
sold pursuant to the underwriters’ option. |
| CUSIP
No. 55287L101 |
| 1. |
Names of Reporting Persons
Genesis VC Partners XVI, LLC |
| 2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨ (b) x
(1) |
| 3. |
SEC
Use Only |
| 4. |
Source of Funds (See Instructions)
AF |
| 5. |
Check
if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨ |
| 6. |
Citizenship or Place of Organization
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
7. |
Sole Voting Power
0 |
| 8. |
Shared Voting Power
2,136,335 shares (2) |
| 9. |
Sole Dispositive Power
0 |
| 10. |
Shared Dispositive Power
2,136,335 shares (2) |
| 11. |
Aggregate Amount Beneficially Owned by Each Reporting Person
2,136,335 shares (2) |
| 12. |
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ |
| 13. |
Percent of Class Represented by Amount in Row (11)
6.4% (3) |
| 14. |
Type of Reporting Person (See Instructions)
OO |
| |
|
|
|
| (1) | This Schedule 13D is filed by the Reporting
Persons. The Reporting Persons expressly disclaim status as a “group” for purposes
of this Schedule 13D. |
| (2) | Shares are directly held by NVP XVI. Genesis
XVI is the general partner of NVP XVI, NVP Associates is the managing member of Genesis XVI,
Crowe and Kossow are Co-Chief Executive Officers of NVP Associates, and Aynechi is an officer
of NVP Associates and a director of the Issuer. Each of Genesis XVI, NVP Associates, Crowe,
Kossow and Aynechi, may be deemed to share voting and investment authority over these shares. |
| (3) | Calculation of the percentage of common stock
beneficially owned is based upon 31,853,698 shares of Common Stock outstanding as of September 16,
2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s
final prospectus filed with the SEC on September 13, 2024 and giving effect to an additional
1,530,000 shares issued and sold pursuant to the underwriters’ option. |
| CUSIP
No. 55287L101 |
| 1. |
Names of Reporting Persons
NVP Associates, LLC |
| 2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨ (b) x
(1) |
| 3. |
SEC
Use Only |
| 4. |
Source of Funds (See Instructions)
AF |
| 5. |
Check
if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨ |
| 6. |
Citizenship or Place of Organization
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
7. |
Sole Voting Power
0 |
| 8. |
Shared Voting Power
2,136,335 shares (2) |
| 9. |
Sole Dispositive Power
0 |
| 10. |
Shared Dispositive Power
2,136,335 shares (2) |
| 11. |
Aggregate Amount Beneficially Owned by Each Reporting Person
2,136,335 shares (2) |
| 12. |
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ |
| 13. |
Percent of Class Represented by Amount in Row (11)
6.4% (3) |
| 14. |
Type of Reporting Person (See Instructions)
OO |
| |
|
|
|
| (1) | This Schedule 13D is filed by the Reporting
Persons. The Reporting Persons expressly disclaim status as a “group” for purposes
of this Schedule 13D. |
| (2) | Shares are directly held by NVP XVI. Genesis
XVI is the general partner of NVP XVI, NVP Associates is the managing member of Genesis XVI,
Crowe and Kossow are Co-Chief Executive Officers of NVP Associates, and Aynechi is an officer
of NVP Associates and a director of the Issuer. Each of Genesis XVI, NVP Associates, Crowe,
Kossow and Aynechi, may be deemed to share voting and investment authority over these shares. |
| (3) | Calculation of the percentage of common stock
beneficially owned is based upon 31,853,698 shares of Common Stock outstanding as of September 16,
2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s
final prospectus filed with the SEC on September 13, 2024 and giving effect to an additional
1,530,000 shares issued and sold pursuant to the underwriters’ option. |
| CUSIP
No. 55287L101 |
| 1. |
Names of Reporting Persons
Jeffrey Crowe |
| 2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨ (b) x
(1) |
| 3. |
SEC
Use Only |
| 4. |
Source of Funds (See Instructions)
AF |
| 5. |
Check
if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨ |
| 6. |
Citizenship or Place of Organization
United States |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
7. |
Sole Voting Power
0 |
| 8. |
Shared Voting Power
2,136,335 shares (2) |
| 9. |
Sole Dispositive Power
0 |
| 10. |
Shared Dispositive Power
2,136,335 shares (2) |
| 11. |
Aggregate Amount Beneficially Owned by Each Reporting Person
2,136,335 shares (2) |
| 12. |
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ |
| 13. |
Percent of Class Represented by Amount in Row (11)
6.4% (3) |
| 14. |
Type of Reporting Person (See Instructions)
IN |
| |
|
|
|
| (1) | This Schedule 13D is filed by the Reporting
Persons. The Reporting Persons expressly disclaim status as a “group” for purposes
of this Schedule 13D. |
| (2) | Shares are directly held by NVP XVI. Genesis
XVI is the general partner of NVP XVI, NVP Associates is the managing member of Genesis XVI,
Crowe and Kossow are Co-Chief Executive Officers of NVP Associates, and Aynechi is an officer
of NVP Associates and a director of the Issuer. Each of Genesis XVI, NVP Associates, Crowe,
Kossow and Aynechi, may be deemed to share voting and investment authority over these shares. |
| (3) | Calculation of the percentage of common stock
beneficially owned is based upon 31,853,698 shares of Common Stock outstanding as of September 16,
2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s
final prospectus filed with the SEC on September 13, 2024 and giving effect to an additional
1,530,000 shares issued and sold pursuant to the underwriters’ option. |
| CUSIP
No. 55287L101 |
| 1. |
Names of Reporting Persons
Jon E. Kossow |
| 2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨ (b) x
(1) |
| 3. |
SEC
Use Only |
| 4. |
Source of Funds (See Instructions)
AF |
| 5. |
Check
if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨ |
| 6. |
Citizenship or Place of Organization
United States |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
7. |
Sole Voting Power
0 |
| 8. |
Shared Voting Power
2,136,335 shares (2) |
| 9. |
Sole Dispositive Power
0 |
| 10. |
Shared Dispositive Power
2,136,335 shares (2) |
| 11. |
Aggregate Amount Beneficially Owned by Each Reporting Person
2,136,335 shares (2) |
| 12. |
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ |
| 13. |
Percent of Class Represented by Amount in Row (11)
6.4% (3) |
| 14. |
Type of Reporting Person (See Instructions)
IN |
| |
|
|
|
| (1) | This Schedule 13D is filed by the Reporting
Persons. The Reporting Persons expressly disclaim status as a “group” for purposes
of this Schedule 13D. |
| (2) | Shares are directly held by NVP XVI. Genesis
XVI is the general partner of NVP XVI, NVP Associates is the managing member of Genesis XVI,
Crowe and Kossow are Co-Chief Executive Officers of NVP Associates, and Aynechi is an officer
of NVP Associates and a director of the Issuer. Each of Genesis XVI, NVP Associates, Crowe,
Kossow and Aynechi, may be deemed to share voting and investment authority over these shares. |
| (3) | Calculation of the percentage of common stock
beneficially owned is based upon 31,853,698 shares of Common Stock outstanding as of September 16,
2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s
final prospectus filed with the SEC on September 13, 2024 and giving effect to an additional
1,530,000 shares issued and sold pursuant to the underwriters’ option. |
| CUSIP
No. 55287L101 |
| 1. |
Names of Reporting Persons
Tiba Aynechi |
| 2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨ (b) x
(1) |
| 3. |
SEC
Use Only |
| 4. |
Source of Funds (See Instructions)
AF |
| 5. |
Check
if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨ |
| 6. |
Citizenship or Place of Organization
United States |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
7. |
Sole Voting Power
0 |
| 8. |
Shared Voting Power
2,136,335 shares (2) |
| 9. |
Sole Dispositive Power
0 |
| 10. |
Shared Dispositive Power
2,136,335 shares (2) |
| 11. |
Aggregate Amount Beneficially Owned by Each Reporting Person
2,136,335 shares (2) |
| 12. |
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ |
| 13. |
Percent of Class Represented by Amount in Row (11)
6.4% (3) |
| 14. |
Type of Reporting Person (See Instructions)
IN |
| |
|
|
|
| (1) | This Schedule 13D is filed by the Reporting
Persons. The Reporting Persons expressly disclaim status as a “group” for purposes
of this Schedule 13D. |
| (2) | Shares are directly held by NVP XVI. Genesis
XVI is the general partner of NVP XVI, NVP Associates is the managing member of Genesis XVI,
Crowe and Kossow are Co-Chief Executive Officers of NVP Associates, and Aynechi is an officer
of NVP Associates and a director of the Issuer. Each of Genesis XVI, NVP Associates, Crowe,
Kossow and Aynechi, may be deemed to share voting and investment authority over these shares. |
| (3) | Calculation of the percentage of common stock
beneficially owned is based upon 31,853,698 shares of Common Stock outstanding as of September 16,
2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s
final prospectus filed with the SEC on September 13, 2024 and giving effect to an additional
1,530,000 shares issued and sold pursuant to the underwriters’ option. |
| Item 1. | Security and Issuer |
The class of equity security to which this statement
on Schedule 13D relates is the Common Stock, $0.0001 par value (“Common Stock”) of MBX Biosciences, Inc., a Delaware
corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 11711 N. Meridian Street, Suite 300,
Carmel, IN 46032. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
| Item 2. | Identity and Background |
| (a) | This Schedule 13D is filed by Norwest Venture
Partners XVI, LP (“NVP XVI”), Genesis VC Partners XVI, LLC (“Genesis XVI”),
NVP Associates, LLC (“NVP Associates”), Jeffrey Crowe (“Crowe”),
Jon E. Kossow (“Kossow”) and Tiba Aynechi (“Aynechi” and, with NVP
XVI, Genesis XVI, NVP Associates, Crowe and Kossow, collectively, the “Reporting Persons”).
The Reporting Persons expressly disclaim status as a “group” for purposes of
this Schedule 13D. |
| (b) | The principal business office of the Reporting
Persons is 1300 El Camino Real, Suite 200, Menlo Park, CA 94025. |
| (c) | The principal business of the Reporting Persons
is venture capital investments. Genesis XVI is the general partner of NVP XVI, NVP Associates
is the managing member of Genesis XVI, Crowe and Kossow are Co-Chief Executive Officers of
NVP Associates, and Aynechi is an officer of NVP Associates. |
| (d) | During the last five years, none of the Reporting
Persons has been convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors). |
| (e) | During the last five years, none of the Reporting
Persons was a party to a civil proceeding of a judicial of administrative body of competent
jurisdiction or were subject to a judgment, decree or final order enjoining future violations
of, or prohibiting or mandating activities subject to, federal or state securities laws or
finding any violation with respect to such laws. |
| (f) | Each of NVP XVI, Genesis XVI and NVP Associates
was organized in the state of Delaware and each of the individuals is a citizen of the United
States. |
| Item 3. | Source and Amount of Funds or
Other Consideration |
Prior to the Issuer’s initial public offering
(the “IPO”), NVP XVI purchased 16,666,666 shares of Series B Preferred Stock for an aggregate purchase price of $14,999,999.40.
On September 6, 2024, the Issuer effected
a 1-for-12.0221 reverse stock split of its common stock and a proportional adjustment to the existing conversion ratios of the Preferred
Stock (the “Reverse Stock Split”). In connection with the closing of the IPO, on September 16, 2024, the Preferred Stock
discussed above automatically converted into shares of Common Stock on a 1-for-12.0221 basis. NVP XVI also purchased 750,000 shares of
Common Stock from the underwriters of the IPO at the IPO price of $16.00 per share, for an aggregate purchase price of $12,000,000.
All purchases of the securities described herein
were for cash and were funded by working capital of NVP XVI.
| Item 4. | Purpose of Transaction |
The Reporting Persons purchased the aforementioned
securities for investment purposes with the aim of increasing the value of their investments and the Issuer. Subject to applicable legal
requirements, one or more of the Reporting Persons may purchase additional securities of the Issuer from time to time in open market
or private transactions, depending on its evaluation of the Issuer’s business, prospects and financial condition, the market for
the Issuer’s securities, other developments concerning the Issuer, the reaction of the Issuer to the Reporting Persons’ ownership
of the Issuer’s securities, other opportunities available to the Reporting Persons, and general economic, money market and stock
market conditions. In addition, depending upon the factors referred to above, the Reporting Persons may dispose of all or a portion of
their securities of the Issuer at any time (including by means of programs adopted pursuant to Rule 10b5-1 under the Securities
Exchange Act of 1934 (the “Act”)). Each of the Reporting Persons reserve the right to increase or decrease its holdings on
such terms and at such times as each may decide.
Except as set forth in this Item 4 and Item 6
below, none of the Reporting Persons have a present plan or proposal that relates to or would result in any of the actions specified
in clauses (a) through (j) of Item 4 of Schedule 13D of the Act. However, each of the Reporting Persons reserves the right
to propose or participate in future transactions which may result in one or more of such actions, including but not limited to, an extraordinary
corporate transaction, such as a merger, reorganization or liquidation, sale of a material amount of assets of the Issuer or its subsidiaries,
or other transactions which might have the effect of causing the Common Stock to become eligible for termination of registration under
Section 12(g) of the Act. The Reporting Persons also retain the right to change their investment intent at any time, to acquire
additional shares of Common Stock or other securities of the Issuer from time to time, or to sell or otherwise dispose of all or part
of the Common Stock beneficially owned by them (or any shares of Common Stock into which such securities are converted) in any manner
permitted by law. The Reporting Persons may engage from time to time in ordinary course transactions with financial institutions with
respect to the securities described herein.
Dr. Tiba Aynechi, an officer of NVP Associates,
is a member of the board of directors of the Issuer. As a director of the Issuer, Dr. Aynechi may have influence over the corporate
activities of the Issuer, including activities which may relate to the transactions described in clauses (a) through (j) of
Item 4 of Schedule 13D.
| Item 5. | Interest in Securities of the
Issuer |
| (a) – (b). |
The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule
13D is provided as of September 23, 2024: |
Reporting
Persons | |
Shares Held
Directly | | |
Sole Voting
Power | | |
Shared
Voting
Power | | |
Sole
Dispositive
Power | | |
Shared
Dispositive
Power | | |
Beneficial
Ownership | | |
Percentage
of Class (2) | |
| NVP XVI (1) | |
| 2,136,335 | | |
| | | |
| 2,136,335 | | |
| | | |
| 2,136,335 | | |
| 2,136,335 | | |
| 6.4 | % |
| Genesis XVI (1) | |
| | | |
| | | |
| 2,136,335 | | |
| | | |
| 2,136,335 | | |
| 2,136,335 | | |
| 6.4 | % |
| NVP Associates (1) | |
| | | |
| | | |
| 2,136,335 | | |
| | | |
| 2,136,335 | | |
| 2,136,335 | | |
| 6.4 | % |
| Crowe (1) | |
| | | |
| | | |
| 2,136,335 | | |
| | | |
| 2,136,335 | | |
| 2,136,335 | | |
| 6.4 | % |
| Kossow (1) | |
| | | |
| | | |
| 2,136,335 | | |
| | | |
| 2,136,335 | | |
| 2,136,335 | | |
| 6.4 | % |
| Aynechi (1) | |
| | | |
| | | |
| 2,136,335 | | |
| | | |
| 2,136,335 | | |
| 2,136,335 | | |
| 6.4 | % |
| (1) | Shares are directly held by NVP XVI. Genesis
XVI is the general partner of NVP XVI, NVP Associates is the managing member of Genesis XVI,
Crowe and Kossow are Co-Chief Executive Officers of NVP Associates, and Aynechi is an officer
of NVP Associates and a director of the Issuer. Each of Genesis XVI, NVP Associates, Crowe,
Kossow and Aynechi, may be deemed to share voting and investment authority over these shares. |
| (2) | Calculation of the percentage of common
stock beneficially owned is based upon 31,853,698 shares of Common Stock outstanding as of
September 16, 2024 upon the closing of the Issuer’s initial public offering, as
reported in the Issuer’s final prospectus filed with the SEC on September 13,
2024 and giving effect to an additional 1,530,000 shares issued and sold pursuant to the
underwriters’ option. |
| (c) | Except as set forth herein, none of the Reporting
Persons has effected any transactions in shares of the Issuer’s Common Stock during
the last 60 days. |
| (d) | No other person is known to have the right
to receive or the power to direct the receipt of dividends from, or any proceeds from the
sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons. |
| Item 6. | Contracts, Arrangements, Understandings
or Relationships with Respect to Securities of the Issuer |
Lock-up Agreements
The holders of substantially all of the Issuer’s
pre-IPO capital stock, including NVP XVI, and each of the Issuer’s directors, entered into lock-up agreements (the “Lock-Up
Agreements”) with the representatives of the underwriters of the Issuer’s IPO. Pursuant to the Lock-Up Agreements, NVP XVI
is not permitted, with limited exceptions, for a period of 180 days from September 12, 2024, to offer, sell, or otherwise transfer
or dispose of any of the Issuer’s securities, without the consent of J.P. Morgan Securities LLC and Jefferies LLC.
The description of the Lock-Up Agreements contained
in this Item 6 is qualified in its entirety by reference to the full text of the form of Lock-up Agreement filed as Exhibit B to
this Schedule 13D and incorporated by reference herein.
Investors’ Rights Agreement
On August 2, 2024, the Issuer, NVP XVI and
certain other parties entered into an amended and restated investors’ rights agreement (the “Investors’ Rights Agreement”).
The Investors’ Rights Agreement provides NVP XVI and other parties thereto with certain demand registration rights, including shelf
registration rights, in respect of the shares of Common Stock issued to it upon conversion of the convertible preferred stock, subject
to certain conditions. In addition, in the event that the Issuer registers additional shares of Common Stock for its own account or for
the account of other holders of its securities, NVP XVI and certain other parties are entitled to include their shares in the registration,
subject to certain limitations. The registration rights will expire on the earliest to occur of (a) the closing of certain liquidation
events, (b) the fifth anniversary of the completion of the IPO or (c) at such time after this offering when the holder’s
shares may be sold without limitation pursuant to Rule 144 or another similar exemption under the Securities Act of 1933, as amended,
during a three-month period without registration and such holder holds less than one percent of the outstanding capital stock of the
Issuer.
The Investors’ Rights Agreement contains
customary cross-indemnification provisions, pursuant to which the Issuer is obligated to indemnify NVP XVI and other parties in the event
of material misstatements or omissions in the registration statement attributable to the Issuer or any violation or alleged violation
whether by action or inaction by the Issuer under certain securities laws and NVP XVI is obligated to indemnify the Issuer for material
misstatements or omissions in the registration statement attributable to it, subject to certain limitations.
The description of the Investors’ Rights
Agreement contained in this Item 6 is qualified in its entirety by reference to the full text of the Investors’ Rights Agreement
filed as Exhibit C to this Schedule 13D and incorporated by reference herein.
Equity Awards
Dr. Tiba Aynechi, an officer of NVP Associates,
is a member of the Board of Directors of the Issuer. From time to time, Dr. Aynechi may receive stock options or other awards of
equity-based compensation pursuant to the Issuer’s compensation arrangements for non-employee directors.
On September 12, 2024 Dr. Aynechi received
an option representing the right to purchase a total of 15,963 shares of the Issuer's Common Stock, 25% of which shall vest and become
exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject
to Dr. Aynechi’s continued service to the Issuer through each such vesting date. These options have an exercise price of $16.00.
| Item 7. | Material to be Filed as Exhibits |
Signature
After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: September 23, 2024
| Norwest Venture Partners XVI, LP |
|
| |
|
|
| By: |
Genesis VC Partners XVI, LLC |
|
| Its |
General Partner |
|
| |
|
|
| By: |
NVP Associates, LLC |
|
| Its |
Managing Member |
|
| |
|
|
| By: |
/s/ Matthew De Dominicis |
|
| |
Name: |
Matthew De Dominicis |
|
| |
Title: |
Chief Financial Officer |
|
| |
|
|
| Genesis VC Partners XVI, LLC |
|
| |
|
|
| By: |
NVP Associates, LLC |
|
| Its |
Managing Member |
|
| |
|
|
| By: |
/s/ Matthew De Dominicis |
|
| |
Name: |
Matthew De Dominicis |
|
| |
Title: |
Chief Financial Officer |
|
| |
|
|
| NVP Associates, LLC |
|
| |
|
|
| By: |
/s/ Matthew De Dominicis |
|
| |
Name: |
Matthew De Dominicis |
|
| |
Title: |
Chief Financial Officer |
|
| /s/ Matthew De Dominicis |
|
| Matthew De Dominicis |
|
| as Attorney-in-fact for Jeffrey Crowe |
|
| |
|
| /s/ Matthew De Dominicis |
|
| Matthew De Dominicis |
|
| as Attorney-in-fact for Jon E. Kossow |
|
| |
|
| /s/ Matthew De Dominicis |
|
| Matthew De Dominicis |
|
| as Attorney-in-fact for Tiba Aynechi |
|
| |
ATTENTION |
|
| Intentional
misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). |
Exhibit(s):
EXHIBIT A
JOINT FILING AGREEMENT
The undersigned hereby agree that a single Schedule
13D (or any amendment thereto) relating to the Common Stock of MBX Biosciences, Inc. shall be filed on behalf of each of the undersigned
and that this Agreement shall be filed as an exhibit to such Schedule 13D.
Dated: September 23, 2024
| Norwest Venture Partners XVI, LP |
|
| |
|
|
| By: |
Genesis VC Partners XVI, LLC |
|
| Its |
General Partner |
|
| |
|
|
| By: |
NVP Associates, LLC |
|
| Its |
Managing Member |
|
| |
|
|
| By: |
/s/ Matthew De Dominicis |
|
| |
Name: |
Matthew De Dominicis |
|
| |
Title: |
Chief Financial Officer |
|
| |
|
|
| Genesis VC Partners XVI, LLC |
|
| |
|
|
| By: |
NVP Associates, LLC |
|
| Its |
Managing Member |
|
| |
|
|
| By: |
/s/ Matthew De Dominicis |
|
| |
Name: |
Matthew De Dominicis |
|
| |
Title: |
Chief Financial Officer |
|
| |
|
|
| NVP Associates, LLC |
|
| |
|
|
| By: |
/s/ Matthew De Dominicis |
|
| |
Name: |
Matthew De Dominicis |
|
| |
Title: |
Chief Financial Officer |
|
| /s/ Matthew De Dominicis |
|
| Matthew De Dominicis |
|
| as Attorney-in-fact for Jeffrey Crowe |
|
| |
|
| /s/ Matthew De Dominicis |
|
| Matthew De Dominicis |
|
| as Attorney-in-fact for Jon E. Kossow |
|
| |
|
| /s/ Matthew De Dominicis |
|
| Matthew De Dominicis |
|
| as Attorney-in-fact for Tiba Aynechi |
|
Grafico Azioni MBX Biosciences (NASDAQ:MBX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni MBX Biosciences (NASDAQ:MBX)
Storico
Da Dic 2023 a Dic 2024
